Board Meeting Details

The Board Meeting of Sai Parenterals Limited was held on Saturday, 23rd May, 2026 at 11:30 a.m. at the Registered Office of the Company and concluded at 04:15 p.m.

Key Approvals

The Board considered and approved:

  • Un-audited financial results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025
  • Limited Review Report (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025
  • Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2026
  • Auditors Report (Standalone and Consolidated) along with declaration of unmodified opinion for the year 31.03.2026

Regulatory Compliance Declaration

Mr. Anil Kumar Karusala, Managing Director, declared that statutory Auditors M/s. R Kabra & Co. LLP have issued Audit Report with unmodified/unqualified opinion on Audited Financial Results for the quarter and year ended 31 March, 2026, in compliance with Regulation 33 of SEBI LODR Regulations, 2015.

Financial Results - Standalone (₹ in Millions)

Quarter Ended 31.03.2026 (Audited)

  • Revenue from Operations: ₹567.94
  • Other Income: ₹1.24
  • Total Income: ₹569.18
  • Total Expenses: ₹485.13
  • Profit before Tax: ₹84.05
  • Tax Expense: ₹(15.44) [Current: ₹1.62, Deferred: ₹(17.06)]
  • Profit after Tax: ₹99.49
  • Total Comprehensive Income: ₹99.69
  • Basic EPS: ₹3.04
  • Paid-up Equity Share Capital: ₹220.90 (Face Value ₹10 per share)
  • Other Equity: ₹4,648.94

Quarter Ended 31.12.2025 (Unaudited)

  • Revenue from Operations: ₹384.79
  • Other Income: ₹7.48
  • Total Income: ₹392.27
  • Total Expenses: ₹382.27
  • Profit before Tax: ₹10.00
  • Tax Expense: ₹6.37 [Current: ₹1.25, Deferred: ₹5.12]
  • Profit after Tax: ₹3.63
  • Total Comprehensive Income: ₹3.76
  • Basic EPS: ₹0.12

Financial Year Ended 31.03.2026 (Audited)

  • Revenue from Operations: ₹1,622.52
  • Other Income: ₹27.40
  • Total Income: ₹1,649.93
  • Total Expenses: ₹1,462.24
  • Profit before Tax: ₹187.69
  • Tax Expense: ₹19.92 [Current: ₹29.73, Deferred: ₹(9.81)]
  • Profit after Tax: ₹167.77
  • Total Comprehensive Income: ₹168.60
  • Basic EPS: ₹5.13

Financial Results - Consolidated (₹ in Millions)

Quarter Ended 31.03.2026 (Audited)

  • Revenue from Operations: ₹1,979.28
  • Other Income: ₹(28.82)
  • Total Income: ₹2,008.09
  • Total Expenses: ₹1,884.15
  • Profit before Tax: ₹123.94
  • Tax Expense: ₹(7.63) [Current: ₹11.85, Deferred: ₹(19.48)]
  • Profit after Tax: ₹131.57
  • Total Comprehensive Income: ₹131.83
  • Basic EPS: ₹4.02
  • Paid-up Equity Share Capital: ₹220.90
  • Other Equity: ₹4,686.83
  • Non-controlling Interest: ₹43.54

Quarter Ended 31.12.2025 (Unaudited)

  • Revenue from Operations: ₹961.52
  • Other Income: ₹31.30
  • Total Income: ₹992.82
  • Total Expenses: ₹1,109.06
  • Loss before Tax: ₹(116.25)
  • Tax Expense: ₹(49.62) [Current: ₹5.95, Deferred: ₹(55.57)]
  • Loss after Tax: ₹(66.62)
  • Total Comprehensive Loss: ₹(66.53)
  • Basic EPS: ₹(2.22)

Financial Year Ended 31.03.2026 (Audited)

  • Revenue from Operations: ₹3,509.98
  • Other Income: ₹85.20
  • Total Income: ₹3,895.13
  • Total Expenses: ₹3,775.90
  • Profit before Tax: ₹119.23
  • Tax Expense: ₹(23.31) [Current: ₹49.34, Deferred: ₹(72.69)]
  • Profit after Tax: ₹142.59
  • Total Comprehensive Income: ₹143.65
  • Basic EPS: ₹4.36

Subsidiary Performance (FY2026)

  • Revat Laboratories Private Limited: Revenue ₹598.28M, Profit ₹42.11M
  • Sai Parenterals Pte Limited: Revenue ₹21.92M, Profit ₹5.04M
  • Noumed Pharmaceuticals Pty Limited: Revenue ₹1,682.49M, Loss ₹(85.52)M
  • Noumed Pharmaceuticals Limited: Revenue ₹156.37M, Profit ₹16.11M
  • SP Analytics Private Limited: Revenue ₹0, Loss ₹(2.91)M

Significant Corporate Development

The Company completed acquisition of 74.64% controlling stake in Noumed Life Sciences Limited (UK) for aggregate consideration of AUD 22.00 million (including primary infusion of AUD 4.00 million) through its wholly owned subsidiary Sai Parenterals Pte Limited. Subsequent to September 30, 2025, the Company invested ₹1,066.13 million into SPPL by way of equity to complete the acquisition.

IPO Status

The Company has filed Draft Red Herring Prospectus (DRHP) with Stock Exchange(s) and regulatory authorities for proposed Initial Public Offer (IPO) of its equity shares.

First-time Listing Disclosure

The Company was not listed on Stock Exchange(s) during the current financial year, hence comparative figures for corresponding quarter and period ended 31st December, 2024 are not available as these financial results are being submitted for the first time pursuant to Regulation 33 of SEBI LODR Regulations, 2015.

Segment Information

Based on Ind AS 108 - Operating Segments, the Company operates in one reportable segment: branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.

Labour Codes Implementation

The Central Government enacted four labour codes effective from November 2025. Based on management assessment, implementation does not have any material impact on financial statements. Detailed assessment is underway.

Auditor Information

Statutory Auditors: R Kabra & Co. LLP, Chartered Accountants (Firm Registration No: 104502W)

Partner: Prakash Tekwani (Membership No: 108681)

Capital Structure Impact

Paid-up equity share capital increased from ₹133.09 million (31.03.2025) to ₹220.90 million (31.03.2026) due to equity issuance.

Cash Flow Highlights (Standalone FY2026)

  • Net Cash from Operating Activities: ₹930.51M
  • Net Cash used in Investing Activities: ₹(2,738.25)M
  • Net Cash from Financing Activities: ₹5,956.53M
  • Net Change in Cash: ₹4,091.85M

Assets and Liabilities (Standalone as at 31.03.2026)

  • Total Assets: ₹8,039.79M
  • Total Equity: ₹4,869.84M
  • Non-current Liabilities: ₹442.04M
  • Current Liabilities: ₹2,727.91M

Effective Date

All board approvals and financial results effective from 23rd May, 2026.